Transcriptional positive cofactor 4 promotes breast cancer proliferation and metastasis through c-Myc mediated Warburg effect

Transcriptional Activation 0301 basic medicine Epithelial-Mesenchymal Transition Proliferation Cell Respiration Breast Neoplasms Metastasis Proto-Oncogene Proteins c-myc 03 medical and health sciences Breast cancer Cell Movement Mice, Inbred NOD Cell Line, Tumor C-Myc Animals Humans Neoplasm Metastasis PC4 Cell Proliferation QH573-671 Research R 3. Good health DNA-Binding Proteins Cell Transformation, Neoplastic Medicine Heterografts Female Warburg effect Cytology Signal Transduction Transcription Factors
DOI: 10.1186/s12964-019-0348-0 Publication Date: 2019-04-16T15:04:04Z
ABSTRACT
The human positive cofactor 4 (PC4) is initially identified as a transcriptional cofactor and has an important role in embryonic development and malignant transformation. However, the clinical significance and the molecular mechanisms of PC4 in breast cancer development and progression are still unknown.We investigated PC4 expression in 114 cases of primary breast cancer and matched normal breast tissue specimens, and studied the impact of PC4 expression as well as the molecular mechanisms of this altered expression on breast cancer growth and metastasis both in vitro and in vivo.PC4 was significantly upregulated in breast cancer and high PC4 expression was positively correlated with metastasis and poor prognosis of patients. Gene set enrichment analysis (GSEA) demonstrated that the gene sets of cell proliferation and Epithelial-Mesenchymal Transition (EMT) were positively correlated with elevated PC4 expression. Consistently, loss of PC4 markedly inhibited the growth and metastasis of breast cancer both in vitro and in vivo. Mechanistically, PC4 exerted its oncogenic functions by directly binding to c-Myc promoters and inducing Warburg effect.Our study reveals for the first time that PC4 promotes breast cancer progression by directly regulating c-Myc transcription to promote Warburg effect, implying a novel therapeutic target for breast cancer.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (57)
CITATIONS (22)